Based on a thorough review of current studies, we surmised that PD-1 or anti-PD-L1 inhibitors are mainly combined with immunotherapy, chemotherapy, and VEGF(R) inhibitors, and identified 10 cutaneous adverse events: vitiligo, bullous dermatitis, PPE syndrome, maculopapular rash, drug eruption, erythema multiform, acneiform rash, cutaneous exfoliation, cutaneous ulceration, urticarial, SJS, and TEN. Here, VEGFA is linked to vitiligo.